Celia Witten, deputy director of the FDA's Center for Biologics Evaluation and Research, has left the FDA, adding to a wave ...

A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...

Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to J&J's blockbuster immunosuppressive ...

As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ...

Eli Lilly has amassed a stockpile of soon-to-be-launched drugs and related materials, primarily its oral GLP-1 candidate ...

The FDA said Friday that the shortage of semaglutide, the main ingredient in Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy, ...

UnitedHealthcare offers voluntary buyouts to 30,000 employees due to low attrition and digital shift, COO Michael Baker tells ...

Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...

Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...

Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare ...

Exelixis and Neurocrine each announce $500M share buybacks; Cosette buys Mayne for $430M; MeiraGTx seeks UK approval for blindness gene therapy; Hookipa ends Poolbeg talks.

Peter Guenter to retire as healthcare CEO, replaced by Danny Bar-Zohar; Matthias Heinzel steps down from life science unit.